Adocia SA (ADOC.PA)
EUR 4.28
(3.39%)
EUR 4.28
(3.39%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.38 Million EUR | -286.7% |
| 2022 | 9.6 Million EUR | 5237.78% |
| 2021 | 180 Thousand EUR | 129.22% |
| 2020 | -616 Thousand EUR | -240.96% |
| 2019 | 437 Thousand EUR | -99.03% |
| 2018 | 45.2 Million EUR | 154.96% |
| 2017 | 17.72 Million EUR | -14.38% |
| 2016 | 20.7 Million EUR | -42.16% |
| 2015 | 35.8 Million EUR | 14031.13% |
| 2014 | -257 Thousand EUR | -105.16% |
| 2013 | 4.97 Million EUR | 57.4% |
| 2012 | 3.16 Million EUR | 183.08% |
| 2011 | 1.11 Million EUR | 585.65% |
| 2010 | -230 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -254 Thousand EUR | 0.0% |
| 2023 Q2 | -9.46 Million EUR | -171.83% |
| 2023 Q3 | -900 Thousand EUR | 90.49% |
| 2023 Q4 | -8.47 Million EUR | -841.44% |
| 2023 Q1 | -3.48 Million EUR | 67.01% |
| 2023 FY | -17.93 Million EUR | -286.7% |
| 2022 Q1 | -2.33 Million EUR | 80.52% |
| 2022 Q2 | -8.07 Million EUR | -246.13% |
| 2022 Q3 | -3.74 Million EUR | 53.62% |
| 2022 Q4 | -10.55 Million EUR | -181.73% |
| 2022 FY | 9.6 Million EUR | 5237.78% |
| 2021 Q1 | -4.46 Million EUR | 65.66% |
| 2021 Q3 | -4.5 Million EUR | 61.12% |
| 2021 Q4 | -11.98 Million EUR | -165.97% |
| 2021 FY | 180 Thousand EUR | 129.22% |
| 2021 Q2 | -11.58 Million EUR | -159.43% |
| 2020 FY | -616 Thousand EUR | -240.96% |
| 2020 Q1 | -5.17 Million EUR | 54.92% |
| 2020 Q2 | -13.94 Million EUR | -169.48% |
| 2020 Q4 | -13 Million EUR | -176.44% |
| 2020 Q3 | -4.7 Million EUR | 66.26% |
| 2019 Q2 | -16.3 Million EUR | -156.38% |
| 2019 FY | 437 Thousand EUR | -99.03% |
| 2019 Q4 | -11.47 Million EUR | -190.25% |
| 2019 Q3 | -3.95 Million EUR | 75.74% |
| 2019 Q1 | -6.35 Million EUR | -400.92% |
| 2018 Q1 | 7.58 Million EUR | 202.24% |
| 2018 Q4 | 2.11 Million EUR | 0.0% |
| 2018 FY | 45.2 Million EUR | 154.96% |
| 2018 Q3 | 2.11 Million EUR | -72.16% |
| 2018 Q2 | 7.58 Million EUR | 0.0% |
| 2017 FY | 17.72 Million EUR | -14.38% |
| 2017 Q4 | -7.42 Million EUR | 0.0% |
| 2017 Q3 | -7.42 Million EUR | -288.04% |
| 2017 Q2 | 3.94 Million EUR | 0.0% |
| 2017 Q1 | 3.94 Million EUR | 339.75% |
| 2016 Q2 | -1.86 Million EUR | 0.0% |
| 2016 Q3 | -1.64 Million EUR | 11.55% |
| 2016 Q1 | -1.86 Million EUR | -164.15% |
| 2016 Q4 | -1.64 Million EUR | 0.0% |
| 2016 FY | 20.7 Million EUR | -42.16% |
| 2015 Q4 | 2.9 Million EUR | 0.0% |
| 2015 FY | 35.8 Million EUR | 14031.13% |
| 2015 Q3 | 2.9 Million EUR | 15.92% |
| 2015 Q2 | 2.5 Million EUR | 0.0% |
| 2015 Q1 | 2.5 Million EUR | 146.17% |
| 2014 Q1 | -2.64 Million EUR | -1132.75% |
| 2014 Q3 | -5.42 Million EUR | -104.7% |
| 2014 Q4 | -5.42 Million EUR | 0.0% |
| 2014 FY | -257 Thousand EUR | -105.16% |
| 2014 Q2 | -2.64 Million EUR | 0.0% |
| 2013 Q1 | -2.18 Million EUR | -8.56% |
| 2013 Q2 | -2.18 Million EUR | 0.0% |
| 2013 Q3 | 256.5 Thousand EUR | 111.76% |
| 2013 Q4 | 256.5 Thousand EUR | 0.0% |
| 2013 FY | 4.97 Million EUR | 57.4% |
| 2012 FY | 3.16 Million EUR | 183.08% |
| 2012 Q4 | -2 Million EUR | 0.0% |
| 2012 Q3 | -2 Million EUR | 0.0% |
| 2011 FY | 1.11 Million EUR | 585.65% |
| 2010 FY | -230 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -124.11% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 64.614% |
| Aelis Farma SA | 12.35 Million EUR | 88.793% |
| Biophytis S.A. | -803 Thousand EUR | 272.478% |
| Advicenne S.A. | 1.42 Million EUR | 2.875% |
| genOway Société anonyme | 20.1 Million EUR | 93.11% |
| IntegraGen SA | 5.01 Million EUR | 72.401% |
| Medesis Pharma S.A. | -2.66 Million EUR | 151.975% |
| Neovacs S.A. | 29.31 Thousand EUR | -4624.705% |
| NFL Biosciences SA | -56.06 Thousand EUR | 2570.391% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 35.669% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 197.584% |
| Sensorion SA | 3.78 Million EUR | 63.436% |
| Theranexus Société Anonyme | -4.63 Million EUR | 129.858% |
| TME Pharma N.V. | -127 Thousand EUR | 1190.551% |
| Valbiotis SA | 2.66 Million EUR | 48.088% |
| TheraVet SA | -530.79 Thousand EUR | 360.929% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -9.313% |
| DBV Technologies S.A. | 4.15 Million EUR | 66.703% |
| Genfit S.A. | 28.22 Million EUR | 95.093% |
| GeNeuro SA | -293.8 Thousand EUR | 571.409% |
| Innate Pharma S.A. | -4.12 Million EUR | 133.608% |
| Inventiva S.A. | 17.5 Million EUR | 92.086% |
| MaaT Pharma SA | 1.65 Million EUR | 16.314% |
| MedinCell S.A. | 9.28 Million EUR | 85.088% |
| Nanobiotix S.A. | 36.2 Million EUR | 96.175% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 37.809% |
| Poxel S.A. | 1000.00 EUR | -138400.0% |
| GenSight Biologics S.A. | 3 Million EUR | 53.833% |
| Transgene SA | -28.4 Million EUR | 104.876% |
| Valneva SE | 52.83 Million EUR | 97.379% |